Developer docs
API playgroundTry for free, no card

Search company profiles

Oxford Phamascience

Full company profile

uuid003ihiq

Namestring
Oxford Phamascience
Legal namestring
Oxford Pharmascience Ltd
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Oxford Pharmascience Ltd is a UK-based specialty pharmaceutical company developing formulation technologies that re-engineer the release and absorption of established drug molecules. Its core asset is the OXPzero™ platform, a proprietary Layered Double Hydroxide (LDH) chemistry in which anionic drug molecules are hosted within positively charged metal hydroxide layers, allowing engineered control of drug release and absorption as independent variables. The lead product, Oxprofen™, is the ibuprofen implementation of the platform and is designed to deliver a median Tmax of approximately 30 minutes in head-to-head human pharmacokinetic studies versus 40–45 minutes for fast-acting ibuprofen lysine, while remaining bioequivalent for AUC and Cmax. The platform architecture is being extended to naproxen, where bioequivalence to naproxen acid has been demonstrated, and is supported by granted and pending patents across major markets.

The company addresses unmet needs in mature NSAID categories by enabling intrinsic taste masking, controlled systemic exposure without elevated peak concentrations, and compatibility with multiple consumer-relevant dosage formats including orally disintegrating tablets, granules, drinks, chewables, hot drinks, and dispersible systems. It pursues both over-the-counter consumer-health applications and prescription acute-pain indications, leveraging established regulatory pathways — 505(b)(2) in the United States and Article 10(3) hybrid in the European Union — that bypass the need for new efficacy trials by relying on the existing safety profiles of ibuprofen and naproxen.

Oxford Pharmascience operates an asset-light, partnership-driven business model. Revenue is intended to be generated through licensing the OXPzero™ platform to pharmaceutical and consumer-health companies, which then handle manufacturing scale-up, regulatory filings in their own names, and downstream commercialisation. The company has historically demonstrated this model through the Ellactiva® soft-chew supplement line, originally launched in the United Kingdom and subsequently distributed in Hong Kong and the Middle East, and licensed to Aché Laborat\u00f3rios for sale in Brazil under its own brand with supply sourced from a Swiss manufacturing partner. As of September 2025, the company is in confidential discussions with several leading pharmaceutical companies to develop and commercialise the Oxprofen™ platform across prescription and OTC pain-relief markets, with API manufacturing economics confirmed at commercial scale.

Short descriptiontext

Oxford Pharmascience is a UK specialty pharmaceutical company developing the proprietary OXPzero™ LDH-chemistry platform to re-engineer NSAID release and absorption, licensing it to pharmaceutical and consumer-health partners through an asset-light model. Its lead product, Oxprofen™, is a fast-acting taste-masked ibuprofen targeting OTC and prescription markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NSAID formulation platform, drug delivery technology, pain relief formulations, pharmaceutical licensing, specialty pharmaceuticals
Industry2 codes
PRIMARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRADAMAC
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Oxford PharmaScience generates revenue through licensing its proprietary OXPzero™ platform technology to pharmaceutical and consumer health companies. The company operates an asset-light model focused on platform development and regulatory enablement while partners handle commercialisation.

oxfordpharmascience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Ellactiva®
Description

Science-led soft-chew supplements consumer-health line, launched originally in the UK and distributed internationally including Hong Kong, Middle East, and Brazil under license through Aché Laboratórios.

oxfordpharmascience.com
+2 more records
Core offering1 text field

Oxford Pharmascience develops and licenses the proprietary OXPzero™ platform, which uses Layered Double Hydroxide (LDH) chemistry to re-engineer existing NSAIDs for faster onset, controlled systemic exposure, intrinsic taste masking, and compatibility with multiple dosage formats. The company licenses this platform and its NSAID implementations (Oxprofen™ for ibuprofen, naproxen extension) to pharmaceutical and consumer health partners for OTC and prescription markets, while also operating the Ellactiva® consumer soft-chew supplement line.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Median Tmax approximately 30 minutes versus 40-45 minutes for fast-acting ibuprofen lysine in head-to-head PK study
+2 more records
Product overview1 text field

Oxford PharmaScience operates a platform-based model centered on the OXPzero™ proprietary NSAID performance platform, which uses Layered Double Hydroxide (LDH) chemistry to engineer drug release and absorption. The primary product is Oxprofen™, the ibuprofen implementation delivering rapid onset (Tmax ≈30 minutes) with controlled exposure, designed for both OTC and prescription acute pain markets via 505(b)(2) regulatory pathways. The platform is being extended to naproxen as a differentiated family of NSAIDs. Separately, the Ellactiva® sub-brand offers science-led soft-chew dietary supplements leveraging the company's formulation expertise for consumer health markets in the UK, Hong Kong, Middle East, and Brazil.

Product and service4 records
1OXPzero™ Platform
CategoryDrug Delivery Platform
Description

Proprietary Layered Double Hydroxide (LDH) chemistry platform that engineers control of NSAID release and absorption as independent variables, enabling rapid onset, controlled systemic exposure, intrinsic taste masking, and compatibility with ODTs, granules, drinks, chewables, and dispersible formats. Licensed to pharmaceutical and consumer health partners.

2Oxprofen™
CategoryNSAID Formulation
Description

Next-generation ibuprofen formulation implementing the OXPzero™ platform, delivering rapid onset (median Tmax ≈30 minutes) with controlled systemic exposure and bioequivalence for AUC and Cmax. Designed for OTC and prescription acute pain markets via the 505(b)(2) regulatory pathway.

3OXPzero™ Naproxen Extension
CategoryNSAID Formulation
Description

Naproxen implementation of the OXPzero™ platform in development, with human PK studies demonstrating bioequivalence to naproxen acid. Supports a differentiated family of NSAIDs under a single IP-protected formulation architecture.

4Ellactiva®
CategoryDietary Supplements
Description

Consumer-health soft-chew dietary supplement line developed using Oxford Pharmascience's formulation and delivery-system expertise. Combines taste with enhanced absorption in a soft-chew format. Originally launched in the UK, distributed in Hong Kong and the Middle East, and licensed in Brazil through Aché Laboratórios.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Confidential Pharmaceutical Partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-15
Description

Oxford PharmaScience is in confidential discussions with several leading pharmaceutical companies to develop and commercialize the Oxprofen platform across prescription and over-the-counter pain-relief markets. API manufacturing economics have been confirmed at commercial scale and taste-masked ODT format developed.

oxfordpharmascience.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Aché Laboratórios, one of Brazil's leading pharmaceutical companies, holds a licence to sell Ellactiva® soft-chew supplement formulations in Brazil. The product is marketed under Aché's own brand, with supply sourced from Oxford's Swiss manufacturing partner.

3Swiss Manufacturing Partner
Strategic tierCoreTypeTechnology or Integration
Description

Oxford PharmaScience sources supply for its Ellactiva® product (sold in Brazil by Aché Laboratórios) from a Swiss manufacturing partner, providing quality manufacturing and supply chain for the consumer health product line.

oxfordpharmascience.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Oxford PharmaScience was founded following research collaborations with the University of Oxford. The company built on early licensed IP from Oxford and has since developed its own proprietary intellectual property portfolio supporting the OXPzero™ platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Belgian specialty pharma that reformulates established drugs using proprietary delivery technology and partners out commercialization, often via hybrid/505(b)(2)-style pathways. Highly comparable platform-play model with a focus on improved versions of off-patent molecules.

TypeDirect peer
Description

Specialty pharma focused on differentiated pain products (abuse-deterrent opioids). Comparable as a pain-focused specialty pharma that builds differentiated formulations of established analgesics for both Rx and OTC-switch lifecycles.

TypeBroad incumbent
Description

Large global OTC and generic pharma platform with major share in OTC analgesics including ibuprofen. Comparable as the dominant incumbent that any differentiated OTC NSAID must displace on shelf, and as a potential commercial partner/competitor.

TypeBroad incumbent
Description

Global CDMO/drug-delivery services company with formulation capabilities spanning oral, ODT, and taste-masking technologies. Comparable as a broader incumbent whose formulation services could either compete with or enable Oxford's OXPzero platform.

TypeBroad incumbent
Description

Large diversified specialty pharma with a substantial OTC consumer-health business (Bausch + Lomb). Comparable as a broad incumbent in OTC pain/consumer health that could be a partner or competitive threat for differentiated NSAID formats.

TypeDirect peer
Description

Specialty pharma (now part of Aytu BioPharma) that uses proprietary drug-delivery technology to develop differentiated, patient-friendly formulations of established CNS drugs. Comparable as a small-cap reformulation platform targeting consumer-relevant format benefits.

TypeDirect peer
Description

Specialty pharma with a proprietary drug-delivery platform (PharmFilm, etc.) that licenses/partnerizes differentiated formulations of established molecules. Closely comparable to Oxford's asset-light model of licensing a proprietary formulation technology to commercial partners.

TypeDirect peer
Description

Specialty pharma that acquires, reformulates, and commercializes established pharmaceutical products. Comparable as a small-cap platform acquiring or developing differentiated formulations of established molecules for niche/commercial channels.

TypeDirect peer
Description

Pain-focused specialty pharma using proprietary drug-delivery technologies (e.g., BEMA) to differentiate established analgesics. Comparable as a delivery-tech-enabled pain franchise built around reformulation of established molecules.

TypeDirect peer
Description

Drug delivery and formulation platform developing differentiated, patient-friendly versions of established molecules via proprietary technologies. Comparable as a technology-driven reformulation specialist with consumer-relevant dosage-format capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oxford Phamascience

Specialty Pharmaceuticalsoxfordpharmascience.com

Oxford Pharmascience is a UK specialty pharmaceutical company developing the proprietary OXPzero™ LDH-chemistry platform to re-engineer NSAID release and absorption, licensing it to pharmaceutical and consumer-health partners through an asset-light model. Its lead product, Oxprofen™, is a fast-acting taste-masked ibuprofen targeting OTC and prescription markets.

What Oxford Phamascience does

Oxford Pharmascience Ltd is a UK-based specialty pharmaceutical company developing formulation technologies that re-engineer the release and absorption of established drug molecules. Its core asset is the OXPzero™ platform, a proprietary Layered Double Hydroxide (LDH) chemistry in which anionic drug molecules are hosted within positively charged metal hydroxide layers, allowing engineered control of drug release and absorption as independent variables. The lead product, Oxprofen™, is the ibuprofen implementation of the platform and is designed to deliver a median Tmax of approximately 30 minutes in head-to-head human pharmacokinetic studies versus 40–45 minutes for fast-acting ibuprofen lysine, while remaining bioequivalent for AUC and Cmax. The platform architecture is being extended to naproxen, where bioequivalence to naproxen acid has been demonstrated, and is supported by granted and pending patents across major markets.

The company addresses unmet needs in mature NSAID categories by enabling intrinsic taste masking, controlled systemic exposure without elevated peak concentrations, and compatibility with multiple consumer-relevant dosage formats including orally disintegrating tablets, granules, drinks, chewables, hot drinks, and dispersible systems. It pursues both over-the-counter consumer-health applications and prescription acute-pain indications, leveraging established regulatory pathways — 505(b)(2) in the United States and Article 10(3) hybrid in the European Union — that bypass the need for new efficacy trials by relying on the existing safety profiles of ibuprofen and naproxen.

Oxford Pharmascience operates an asset-light, partnership-driven business model. Revenue is intended to be generated through licensing the OXPzero™ platform to pharmaceutical and consumer-health companies, which then handle manufacturing scale-up, regulatory filings in their own names, and downstream commercialisation. The company has historically demonstrated this model through the Ellactiva® soft-chew supplement line, originally launched in the United Kingdom and subsequently distributed in Hong Kong and the Middle East, and licensed to Aché Laborat\u00f3rios for sale in Brazil under its own brand with supply sourced from a Swiss manufacturing partner. As of September 2025, the company is in confidential discussions with several leading pharmaceutical companies to develop and commercialise the Oxprofen™ platform across prescription and OTC pain-relief markets, with API manufacturing economics confirmed at commercial scale.

Oxford Phamascience firmographics

Firmographics
Name
Oxford Phamascience
Legal name
Oxford Pharmascience Ltd
Website
https://oxfordpharmascience.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Oxford Pharmascience is a UK specialty pharmaceutical company developing the proprietary OXPzero™ LDH-chemistry platform to re-engineer NSAID release and absorption, licensing it to pharmaceutical and consumer-health partners through an asset-light model. Its lead product, Oxprofen™, is a fast-acting taste-masked ibuprofen targeting OTC and prescription markets.
Ownership category
akta.pro rank

Oxford Phamascience industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRADAMAC
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • NSAID formulation platform
  • Drug delivery technology
  • Pain relief formulations
  • Pharmaceutical licensing
  • Specialty pharmaceuticals

Where Oxford Phamascience is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Oxford Phamascience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and Partnership Revenue: Oxford PharmaScience generates revenue through licensing its proprietary OXPzero™ platform technology to pharmaceutical and consumer health companies. The company operates an asset-light model focused on platform development and regulatory enablement while partners handle commercialisation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Oxford Phamascience product offering

Product offering

Core offering

Oxford Pharmascience develops and licenses the proprietary OXPzero™ platform, which uses Layered Double Hydroxide (LDH) chemistry to re-engineer existing NSAIDs for faster onset, controlled systemic exposure, intrinsic taste masking, and compatibility with multiple dosage formats. The company licenses this platform and its NSAID implementations (Oxprofen™ for ibuprofen, naproxen extension) to pharmaceutical and consumer health partners for OTC and prescription markets, while also operating the Ellactiva® consumer soft-chew supplement line.

Product overview

Oxford PharmaScience operates a platform-based model centered on the OXPzero™ proprietary NSAID performance platform, which uses Layered Double Hydroxide (LDH) chemistry to engineer drug release and absorption. The primary product is Oxprofen™, the ibuprofen implementation delivering rapid onset (Tmax ≈30 minutes) with controlled exposure, designed for both OTC and prescription acute pain markets via 505(b)(2) regulatory pathways. The platform is being extended to naproxen as a differentiated family of NSAIDs. Separately, the Ellactiva® sub-brand offers science-led soft-chew dietary supplements leveraging the company's formulation expertise for consumer health markets in the UK, Hong Kong, Middle East, and Brazil.

Differentiator

Problem solved

Functional benefit

Brands

  • Ellactiva®: Science-led soft-chew supplements consumer-health line, launched originally in the UK and distributed internationally including Hong Kong, Middle East, and Brazil under license through Aché Laboratórios.
  • OXPzero™
  • Oxprofen™

Products and services

  • OXPzero™ Platform Proprietary Layered Double Hydroxide (LDH) chemistry platform that engineers control of NSAID release and absorption as independent variables, enabling rapid onset, controlled systemic exposure, intrinsic taste masking, and compatibility with ODTs, granules, drinks, chewables, and dispersible formats. Licensed to pharmaceutical and consumer health partners.
  • Oxprofen™ Next-generation ibuprofen formulation implementing the OXPzero™ platform, delivering rapid onset (median Tmax ≈30 minutes) with controlled systemic exposure and bioequivalence for AUC and Cmax. Designed for OTC and prescription acute pain markets via the 505(b)(2) regulatory pathway.
  • OXPzero™ Naproxen Extension Naproxen implementation of the OXPzero™ platform in development, with human PK studies demonstrating bioequivalence to naproxen acid. Supports a differentiated family of NSAIDs under a single IP-protected formulation architecture.
  • Ellactiva® Consumer-health soft-chew dietary supplement line developed using Oxford Pharmascience's formulation and delivery-system expertise. Combines taste with enhanced absorption in a soft-chew format. Originally launched in the UK, distributed in Hong Kong and the Middle East, and licensed in Brazil through Aché Laboratórios.

Quantifiable outcome

  • Median Tmax approximately 30 minutes versus 40-45 minutes for fast-acting ibuprofen lysine in head-to-head PK study
  • +2 more outcomes

Companies that use Oxford Phamascience

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Oxford Phamascience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Oxford Phamascience partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • Confidential Pharmaceutical PartnersflagshipStrategic or Co-development Partner · 15 September 2025Oxford PharmaScience is in confidential discussions with several leading pharmaceutical companies to develop and commercialize the Oxprofen platform across prescription and over-the-counter pain-relief markets. API manufacturing economics have been confirmed at commercial scale and taste-masked ODT format developed.
  • Aché LaboratórioscoreChannel Partner/ Reseller/ DistributorAché Laboratórios, one of Brazil's leading pharmaceutical companies, holds a licence to sell Ellactiva® soft-chew supplement formulations in Brazil. The product is marketed under Aché's own brand, with supply sourced from Oxford's Swiss manufacturing partner.
  • Swiss Manufacturing PartnercoreTechnology or IntegrationOxford PharmaScience sources supply for its Ellactiva® product (sold in Brazil by Aché Laboratórios) from a Swiss manufacturing partner, providing quality manufacturing and supply chain for the consumer health product line.
  • University of OxfordcoreStrategic or Co-development PartnerOxford PharmaScience was founded following research collaborations with the University of Oxford. The company built on early licensed IP from Oxford and has since developed its own proprietary intellectual property portfolio supporting the OXPzero™ platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Oxford Phamascience competitors and assessment

Company assessment

Direct peers

  • Hyloris Pharmaceuticals: Belgian specialty pharma that reformulates established drugs using proprietary delivery technology and partners out commercialization, often via hybrid/505(b)(2)-style pathways. Highly comparable platform-play model with a focus on improved versions of off-patent molecules.
  • Collegium Pharmaceutical: Specialty pharma focused on differentiated pain products (abuse-deterrent opioids). Comparable as a pain-focused specialty pharma that builds differentiated formulations of established analgesics for both Rx and OTC-switch lifecycles.
  • Neos Therapeutics: Specialty pharma (now part of Aytu BioPharma) that uses proprietary drug-delivery technology to develop differentiated, patient-friendly formulations of established CNS drugs. Comparable as a small-cap reformulation platform targeting consumer-relevant format benefits.
  • Aquestive Therapeutics: Specialty pharma with a proprietary drug-delivery platform (PharmFilm, etc.) that licenses/partnerizes differentiated formulations of established molecules. Closely comparable to Oxford's asset-light model of licensing a proprietary formulation technology to commercial partners.
  • Harrow Health: Specialty pharma that acquires, reformulates, and commercializes established pharmaceutical products. Comparable as a small-cap platform acquiring or developing differentiated formulations of established molecules for niche/commercial channels.
  • BioDelivery Sciences International: Pain-focused specialty pharma using proprietary drug-delivery technologies (e.g., BEMA) to differentiate established analgesics. Comparable as a delivery-tech-enabled pain franchise built around reformulation of established molecules.
  • Adare Pharmaceuticals: Drug delivery and formulation platform developing differentiated, patient-friendly versions of established molecules via proprietary technologies. Comparable as a technology-driven reformulation specialist with consumer-relevant dosage-format capabilities.

Broad incumbents

  • Perrigo Company: Large global OTC and generic pharma platform with major share in OTC analgesics including ibuprofen. Comparable as the dominant incumbent that any differentiated OTC NSAID must displace on shelf, and as a potential commercial partner/competitor.
  • Catalent: Global CDMO/drug-delivery services company with formulation capabilities spanning oral, ODT, and taste-masking technologies. Comparable as a broader incumbent whose formulation services could either compete with or enable Oxford's OXPzero platform.
  • Bausch Health: Large diversified specialty pharma with a substantial OTC consumer-health business (Bausch + Lomb). Comparable as a broad incumbent in OTC pain/consumer health that could be a partner or competitive threat for differentiated NSAID formats.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Oxford Phamascience social profiles

Digital presence

Oxford Phamascience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oxford Phamascience leadership team

Management profile

Number of profiles

Profiles2 records

Oxford Phamascience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oxford Phamascience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Phamascience

What does Oxford Phamascience do?

Oxford Pharmascience develops and licenses the proprietary OXPzero™ platform, which uses Layered Double Hydroxide (LDH) chemistry to re-engineer existing NSAIDs for faster onset, controlled systemic exposure, intrinsic taste masking, and compatibility with multiple dosage formats. The company licenses this platform and its NSAID implementations (Oxprofen™ for ibuprofen, naproxen extension) to pharmaceutical and consumer health partners for OTC and prescription markets, while also operating the Ellactiva® consumer soft-chew supplement line.

Is Oxford Phamascience a public or private company?

Oxford Phamascience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oxford Phamascience founded?

Oxford Phamascience was founded in 2008. It employs 1 to 10 people.

Where is Oxford Phamascience based?

Oxford Phamascience is headquartered in London, United Kingdom, in the Europe region.

How does Oxford Phamascience make money?

One revenue line is on record: licensing and Partnership Revenue.

Who are Oxford Phamascience's main competitors?

Direct peers on record are Hyloris Pharmaceuticals, Collegium Pharmaceutical, Neos Therapeutics, Aquestive Therapeutics, Harrow Health, BioDelivery Sciences International and Adare Pharmaceuticals. Broad incumbents are Perrigo Company, Catalent and Bausch Health.

Does Oxford Phamascience have an API?

No public API is recorded for Oxford Phamascience.

What industry is Oxford Phamascience in?

Oxford Phamascience's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics), with a secondary code of CRADAMAC, OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales